Literature DB >> 25815845

Novel therapeutic targets of tumor metabolism.

Rigel J Kishton1, Jeffrey C Rathmell.   

Abstract

The study of tumor metabolism has resulted in new understandings of how cancer cells modify metabolic pathways that control cellular energetics to allow increased proliferation and survival. Tumor cells have been shown to alter metabolic pathways involved in glucose, glutamine, and mitochondrial metabolism to generate raw materials needed for rapid cellular proliferation, maintain favorable cellular redox environments, modify cellular epigenetics, and even promote and maintain oncogenic transformation. As a consequence, there has been intense scientific and clinical interest in targeting metabolic alterations that are commonly adopted by tumor cells for therapeutic purposes. In this review, we describe common metabolic alterations seen in tumor cells and discuss how these alterations are being investigated as potential targets for pharmacological intervention in preclinical and clinical settings. We also discuss some of the challenges associated with using tumor metabolism as a therapeutic target in cancer therapy, along with potential avenues to overcome these challenges.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25815845      PMCID: PMC4380246          DOI: 10.1097/PPO.0000000000000099

Source DB:  PubMed          Journal:  Cancer J        ISSN: 1528-9117            Impact factor:   3.360


  105 in total

1.  On the origin of cancer cells.

Authors:  O WARBURG
Journal:  Science       Date:  1956-02-24       Impact factor: 47.728

2.  A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth.

Authors:  Sébastien Bonnet; Stephen L Archer; Joan Allalunis-Turner; Alois Haromy; Christian Beaulieu; Richard Thompson; Christopher T Lee; Gary D Lopaschuk; Lakshmi Puttagunta; Sandra Bonnet; Gwyneth Harry; Kyoko Hashimoto; Christopher J Porter; Miguel A Andrade; Bernard Thebaud; Evangelos D Michelakis
Journal:  Cancer Cell       Date:  2007-01       Impact factor: 31.743

3.  Evidence that glutamine, not sugar, is the major energy source for cultured HeLa cells.

Authors:  L J Reitzer; B M Wice; D Kennell
Journal:  J Biol Chem       Date:  1979-04-25       Impact factor: 5.157

4.  Multiple myeloma exhibits novel dependence on GLUT4, GLUT8, and GLUT11: implications for glucose transporter-directed therapy.

Authors:  Samuel K McBrayer; Javelin C Cheng; Seema Singhal; Nancy L Krett; Steven T Rosen; Mala Shanmugam
Journal:  Blood       Date:  2012-03-27       Impact factor: 22.113

5.  Glucose addiction of TSC null cells is caused by failed mTORC1-dependent balancing of metabolic demand with supply.

Authors:  Andrew Y Choo; Sang Gyun Kim; Matthew G Vander Heiden; Sarah J Mahoney; Hieu Vu; Sang-Oh Yoon; Lewis C Cantley; John Blenis
Journal:  Mol Cell       Date:  2010-05-28       Impact factor: 17.970

6.  An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.

Authors:  Dan Rohle; Janeta Popovici-Muller; Nicolaos Palaskas; Sevin Turcan; Christian Grommes; Carl Campos; Jennifer Tsoi; Owen Clark; Barbara Oldrini; Evangelia Komisopoulou; Kaiko Kunii; Alicia Pedraza; Stefanie Schalm; Lee Silverman; Alexandra Miller; Fang Wang; Hua Yang; Yue Chen; Andrew Kernytsky; Marc K Rosenblum; Wei Liu; Scott A Biller; Shinsan M Su; Cameron W Brennan; Timothy A Chan; Thomas G Graeber; Katharine E Yen; Ingo K Mellinghoff
Journal:  Science       Date:  2013-04-04       Impact factor: 47.728

7.  Fructose 2,6-bisphosphate, the probably structure of the glucose- and glucagon-sensitive stimulator of phosphofructokinase.

Authors:  E Van Schaftingen; L Hue; H G Hers
Journal:  Biochem J       Date:  1980-12-15       Impact factor: 3.857

8.  Glucose transporter 1-mediated glucose uptake is limiting for B-cell acute lymphoblastic leukemia anabolic metabolism and resistance to apoptosis.

Authors:  T Liu; R J Kishton; A N Macintyre; V A Gerriets; H Xiang; X Liu; E D Abel; D Rizzieri; J W Locasale; J C Rathmell
Journal:  Cell Death Dis       Date:  2014-10-16       Impact factor: 8.469

9.  Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis.

Authors:  M I Koukourakis; A Giatromanolaki; E Sivridis; G Bougioukas; V Didilis; K C Gatter; A L Harris
Journal:  Br J Cancer       Date:  2003-09-01       Impact factor: 7.640

10.  Clinical significance of L-type amino acid transporter 1 expression as a prognostic marker and potential of new targeting therapy in biliary tract cancer.

Authors:  Kyoichi Kaira; Yutaka Sunose; Yasuhiro Ohshima; Noriko S Ishioka; Kazuhisa Arakawa; Tetsushi Ogawa; Noriaki Sunaga; Kimihiro Shimizu; Hideyuki Tominaga; Noboru Oriuchi; Hideaki Itoh; Shushi Nagamori; Yoshikatsu Kanai; Aiko Yamaguchi; Atsuki Segawa; Munenori Ide; Masatomo Mori; Tetsunari Oyama; Izumi Takeyoshi
Journal:  BMC Cancer       Date:  2013-10-16       Impact factor: 4.430

View more
  19 in total

Review 1.  Immune Cell Metabolism in Systemic Lupus Erythematosus.

Authors:  Seung-Chul Choi; Anton A Titov; Ramya Sivakumar; Wei Li; Laurence Morel
Journal:  Curr Rheumatol Rep       Date:  2016-11       Impact factor: 4.592

Review 2.  Pheochromocytoma: Gasping for Air.

Authors:  Ivana Jochmanová; Zhengping Zhuang; Karel Pacak
Journal:  Horm Cancer       Date:  2015-07-03       Impact factor: 3.869

Review 3.  Autophagy and Tumor Metabolism.

Authors:  Alec C Kimmelman; Eileen White
Journal:  Cell Metab       Date:  2017-05-02       Impact factor: 27.287

Review 4.  Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy.

Authors:  Rigel J Kishton; Madhusudhanan Sukumar; Nicholas P Restifo
Journal:  Cell Metab       Date:  2017-07-05       Impact factor: 27.287

Review 5.  Metabolic Imaging of Glutamine in Cancer.

Authors:  Lin Zhu; Karl Ploessl; Rong Zhou; David Mankoff; Hank F Kung
Journal:  J Nucl Med       Date:  2017-02-23       Impact factor: 10.057

6.  Global and targeted serum metabolic profiling of colorectal cancer progression.

Authors:  Yin Long; Beatriz Sanchez-Espiridion; Moubin Lin; Lindsey White; Lopa Mishra; Gottumakkala S Raju; Scott Kopetz; Cathy Eng; Michelle A T Hildebrandt; David W Chang; Yuanqing Ye; Dong Liang; Xifeng Wu
Journal:  Cancer       Date:  2017-06-22       Impact factor: 6.860

Review 7.  Tumor microenvironment metabolites directing T cell differentiation and function.

Authors:  Xia Liu; Daniel F Hoft; Guangyong Peng
Journal:  Trends Immunol       Date:  2021-12-29       Impact factor: 16.687

8.  First-in-Human PET Imaging and Estimated Radiation Dosimetry of l-[5-11C]-Glutamine in Patients with Metastatic Colorectal Cancer.

Authors:  Allison S Cohen; Joe Grudzinski; Gary T Smith; Todd E Peterson; Jennifer G Whisenant; Tiffany L Hickman; Kristen K Ciombor; Dana Cardin; Cathy Eng; Laura W Goff; Satya Das; Robert J Coffey; Jordan D Berlin; H Charles Manning
Journal:  J Nucl Med       Date:  2021-04-30       Impact factor: 11.082

Review 9.  Optimizing NK Cell-Based Immunotherapy in Myeloid Leukemia: Abrogating an Immunosuppressive Microenvironment.

Authors:  Natasha Mupeta Kaweme; Fuling Zhou
Journal:  Front Immunol       Date:  2021-06-17       Impact factor: 7.561

10.  Normalization of Enzyme Expression and Activity Regulating Vitamin A Metabolism Increases RAR-Beta Expression and Reduces Cellular Migration and Proliferation in Diseases Caused by Tuberous Sclerosis Gene Mutations.

Authors:  Elhusseiny Mohamed Mahmoud Abdelwahab; Judit Bovari-Biri; Gabor Smuk; Tunde Harko; Janos Fillinger; Judit Moldvay; Vera P Krymskaya; Judit E Pongracz
Journal:  Front Oncol       Date:  2021-06-11       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.